Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation
Yongxing Wang, Young-Ah Suh, Maren Y. Fuller, James G. Jackson, Shunbin Xiong, Tamara Terzian, Alfonso Quintás-Cardama, James A. Bankson, Adel K. El-Naggar, Guillermina Lozano
Yongxing Wang, Young-Ah Suh, Maren Y. Fuller, James G. Jackson, Shunbin Xiong, Tamara Terzian, Alfonso Quintás-Cardama, James A. Bankson, Adel K. El-Naggar, Guillermina Lozano
View: Text | PDF
Research Article Oncology

Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation

  • Text
  • PDF
Abstract

The transcription factor p53 is a tumor suppressor. As such, the P53 gene is frequently altered in human cancers. However, over 80% of the P53 mutations found in human cancers are missense mutations that lead to expression of mutant proteins that not only lack p53 transcriptional activity but exhibit new functions as well. Recent studies show that restoration of p53 expression leads to tumor regression in mice carrying p53 deletions. However, the therapeutic efficacy of restoring p53 expression in tumors containing p53 missense mutations has not been evaluated. Here we demonstrate that restoring wild-type p53 expression halted tumor growth in mice inheriting a p53R172H missense mutation that is equivalent to a P53 missense mutation detected in approximately 6% of human cancers. However, it did not lead to tumor regression, as was observed in mice lacking p53. We further showed that the dominant-negative effect of the mutant p53 encoded by p53R172H dampened the activity of the restored wild-type p53. We therefore conclude that in a mutant p53 background, p53 restoration has the therapeutic potential to suppress tumor progression. Our findings support using p53 restoration as a strategy to treat human cancers with P53 missense mutations and provide direction for optimizing p53 restoration in cancer therapy.

Authors

Yongxing Wang, Young-Ah Suh, Maren Y. Fuller, James G. Jackson, Shunbin Xiong, Tamara Terzian, Alfonso Quintás-Cardama, James A. Bankson, Adel K. El-Naggar, Guillermina Lozano

×

Figure 7

p53R172H dampened the transcription activity of the restored wild-type p53.

Options: View larger image (or click on image) Download as PowerPoint
p53R172H dampened the transcription activity of the restored wild-type p...
(A) Representative images of SA-β-gal assays and p16 and Dec1 staining of tamoxifen-treated p53neo/–Cre-ERTM and p53neo/R172HCre-ERTM angiosarcomas. Scale bar: 100 μm. (B) Percentage of SA-β-gal–, p16-, and Dec1-positive staining cells in p53neo/–Cre-ERTM and p53neo/R172HCre-ERTM angiosarcomas. (C) Comparison of mRNA levels of p21 and cyclin G1 (Ccng1) in p53neo/–Cre-ERTM and p53neo/R172HCre-ERTM angiosarcomas using real-time RT-PCR. p53neo/R172H cells without Cre-ERTM were used as controls. (B and C) Horizontal bars indicate the mean, and symbols indicate individual angiosarcomas. (D) Western blot analyses of p53, p21, and cyclin G1 (Ccng1) protein levels in control and tamoxifen-treated tumors. Protein levels were normalized to actin. (E) Recombination in p53neo/–Cre-ERTM and p53neo/R172HCre-ERTM tumor cell lines after 4-hydroxy-tamoxifen treatment. The results are presented as the mean ± SEM of 3 assays. (F) Comparison of DNA binding by p53 to p21 and puma promoters in p53neo/–Cre-ERTM and p53neo/R172HCre-ERTM tumor cells using ChIP assays. The acetylcholine receptor (AchR) promoter was used as a control, and the results are presented as percentage of input. Data are representative of 2 ChIP experiments performed in triplicate. (G) Comparison of mRNA levels of p21 and puma in p53neo/–Cre-ERTM and p53neo/R172HCre-ERTM tumor cells with (+) and without (–) 4-hydroxy-tamoxifen treatment, using real-time RT-PCR analysis. The results are presented as the mean ± SEM of 3 assays.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts